Shanghai Junshi Biosciences Co., Ltd. Class H (HK:1877) has released an update.
Shanghai Junshi Biosciences Co., Ltd. has received approval from the UK Medicines and Healthcare products Regulatory Agency for its drug Toripalimab, marketed as LOQTORZI® in the UK. This approval allows its use in combination therapies for treating nasopharyngeal carcinoma (NPC) and esophageal squamous cell carcinoma (ESCC), marking it as a pioneering treatment in the UK for these cancers. The clinical trials demonstrated significant improvements in survival rates, highlighting the drug’s potential impact on patient outcomes.
For further insights into HK:1877 stock, check out TipRanks’ Stock Analysis page.